

International Journal of Emerging Research in Applied Medical Sciences (IJERAMS)

Current Advances in Lung Cancer Chemotherapy and Systemic Treatment: A Comprehensive Review

Dr. Vishal Rastogi¹, Mr. Vikas Yadav², Mr. Shatrughna U. Nagrik³, Miss. Bindu Gajanan⁴

¹Professor Satyajeet College of Pharmacy, Mehkar, India, vishalrastoogi@gmail.com

²Associate Professor Satyajeet College of Pharmacy, Mehkar, India, viikasyadav94@gmail.com

³Professor, Department of Pharmaceutics, Satyajeet College of Pharmacy, Mehkar, India, rahulnagriik96@gmail.com

⁴Professor, Satyajeet College of Pharmacy, Mehkar, India, bindugajanan@gmail.com

ABSTRACT

Lung cancer is a leading cause of cancer-related deaths worldwide. Chemotherapy, a systemic treatment, plays a crucial role in managing this disease. This review delves into the principles of chemotherapy for lung cancer, focusing on commonly used drugs, administration methods, and potential side effects. Additionally, it explores the integration of chemotherapy with other treatment modalities, such as surgery, radiation therapy, targeted therapy, and immunotherapy, in a comprehensive approach to lung cancer management. While chemotherapy offers significant benefits, it's essential to acknowledge its potential side effects and discuss strategies for their management. By understanding the nuances of chemotherapy and its role in the broader context of lung cancer treatment, healthcare providers can optimize patient care and improve outcomes for individuals affected by this disease.

Keywords: Lung cancer, chemotherapy, treatment, cancer, drugs, side effects, surgery, radiation therapy, targeted therapy, immunotherapy, healthcare

Article History

Received: 10 April 2026; **Accepted:** 15 April 2026; **Published:** 25 April 2026

Citation

Rastogi. V., (2026). Current Advances in Lung Cancer Chemotherapy and Systemic Treatment: A Comprehensive Review. *International Journal of Emerging Research in Applied Medical Sciences (IJERAMS)*, 2(4), 19-23.

DOI: <https://doi.org/10.65477/2026.v.2i.4.03>

This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author(s) and the source are properly cited.

1. Introduction

Lung cancer remains a significant global health concern, claiming millions of lives annually. Despite advancements in diagnostic techniques and therapeutic approaches, it continues to pose a formidable challenge to healthcare providers worldwide. Chemotherapy, a cornerstone of lung cancer treatment, has evolved significantly, offering promising outcomes for patients with various stages of the disease.

This review aims to provide a comprehensive overview of chemotherapy in lung cancer, delving into its mechanisms of action, commonly employed regimens, and associated side effects. Furthermore, the integration of chemotherapy with other modalities, such as surgery, radiation therapy, targeted therapy, and immunotherapy, will be explored. By understanding the nuances of chemotherapy and its role within a multidisciplinary

approach, healthcare professionals can optimize treatment strategies and improve patient outcomes.

Causes

Causes of Lung Cancer

While the exact causes of lung cancer are complex and not fully understood, several well-established risk factors contribute to its development.

Primary Risk Factor:

Smoking:

- Cigarette smoking is the leading cause of lung cancer.
- The longer and more heavily a person smokes, the greater their risk.
- Secondhand smoke also significantly increases the risk of lung cancer.

Other Risk Factors:


- Exposure to carcinogens:
- Workplace exposure: Asbestos, radon, arsenic, chromium, nickel, and other substances can increase the risk.
- Environmental exposure: Air pollution, especially from diesel exhaust and industrial emissions.
- Family history: A family history of lung cancer can increase the risk.
- Certain medical conditions: Conditions like chronic obstructive pulmonary disease (COPD) and pulmonary fibrosis.
- Previous radiation therapy to the chest: For other cancers, such as breast cancer or lymphoma.

It's important to note that while these factors increase the risk of lung cancer, they do not guarantee its development. Additionally, some people develop lung cancer without any identifiable risk factors.

Treatment

The treatment for lung cancer depends on several factors, including the type of lung cancer (small cell lung cancer or non-small cell lung cancer), the stage of the cancer, and the overall health of the patient.

? ? ? ?



? ? ? ? ? ?
? ? ? ?

Common Treatment Options:

- Surgery:
- Removal of the cancerous lung tissue.
- Suitable for early-stage lung cancer.
- Chemotherapy:
- Use of drugs to kill cancer cells.
- Can be used alone or in combination with other treatments.
- Commonly used drugs include platinum-based drugs (cisplatin, carboplatin) and taxanes (paclitaxel, docetaxel).
- Radiation Therapy:
- Use of high-energy rays to kill cancer cells.
- Can be used to shrink tumors before surgery or to relieve symptoms.
- Targeted Therapy:
- Drugs that target specific molecules involved in cancer cell growth.
- Effective for certain types of lung cancer with specific genetic mutations.
- Immunotherapy:
- Boosts the body's immune system to fight cancer cells.

- Can be used alone or in combination with other treatments.

Combination Therapy:

Often, a combination of these treatments is used to maximize effectiveness and minimize side effects. The specific combination will depend on the individual patient's circumstances.

Palliative Care:

For advanced-stage lung cancer, palliative care focuses on managing symptoms and improving quality of life. This may include pain management, symptom relief, and emotional support.

It's Important to consult with a healthcare professional to discuss the best treatment options for your specific situation.

A Deeper Dive Into Lung Cancer Treatment

Understanding the Basics

We've already discussed the primary treatments for lung cancer: surgery, chemotherapy, radiation therapy, targeted therapy, and immunotherapy. Let's delve a bit deeper into each:

Surgery:

- Lobectomy: Removal of a lobe of the lung.
- Pneumonectomy: Removal of an entire lung.
- Wedge resection: Removal of a small, wedge-shaped section of lung tissue.

Chemotherapy:

- Platinum-based drugs: Cisplatin and carboplatin are commonly used.
- Taxanes: Paclitaxel and docetaxel are other common drugs.
- Radiation Therapy:
- External beam radiation therapy: Radiation is delivered from a machine outside the body.
- Internal radiation therapy (brachytherapy): Radioactive seeds are implanted directly into the tumor.

Targeted Therapy:

- Drugs that target specific molecules in cancer cells.
- Examples include EGFR inhibitors (e.g., erlotinib, gefitinib) and ALK inhibitors (e.g., crizotinib).

Immunotherapy:

- Boosts the body's immune system to fight cancer cells.
- Examples include PD-1 inhibitors (e.g., pembrolizumab, nivolumab).

Advanced Treatment Strategies

- Combination Therapy:
- Combining two or more treatments to maximize effectiveness and minimize side effects.
- For example, chemotherapy and radiation therapy, or chemotherapy and immunotherapy.
- Minimally Invasive Surgery:
- Less invasive surgical techniques, such as video-assisted thoracic surgery (VATS), can reduce recovery time and complications.
- Clinical Trials:

- Participating in clinical trials can provide access to new and experimental treatments.
- Managing Side Effects

Chemotherapy and radiation therapy can cause side effects, such as:

- Fatigue
- Hair loss
- Nausea and vomiting
- Mouth sores
- Loss of appetite
- Bone marrow suppression

Healthcare providers can help manage these side effects with medications, supportive care, and other strategies. Remember: Treatment plans are highly individualized and should be discussed with a healthcare professional. The goal is to develop a personalized treatment plan that maximizes the benefits and minimizes the risks.

Precautions

Precautions to Reduce Lung Cancer Risk

While there's no guaranteed way to prevent lung cancer, several lifestyle changes and preventative measures can significantly reduce your risk:

Primary Prevention

- **Avoid Smoking:** The most significant risk factor for lung cancer is smoking. Quitting smoking is the best way to reduce your risk.
- **Avoid Secondhand Smoke:** Exposure to secondhand smoke can also increase your risk of lung cancer.

CONCLUSION

Lung cancer remains a significant global health challenge, but advancements in diagnosis and treatment have improved patient outcomes. While smoking is the primary risk factor, other factors like exposure to carcinogens and family history also play a role. Early detection and prompt treatment are crucial for better prognosis. Treatment options include surgery, chemotherapy, radiation therapy, targeted therapy, and immunotherapy. The choice of treatment depends on various factors, including the stage of the cancer, the

Secondary Prevention

- **Regular Check-ups:**
- **Annual Physical Exams:** Regular check-ups can help identify potential health problems early.
- **Lung Cancer Screening:** If you are a high-risk individual (heavy smoker or former smoker), consider discussing lung cancer screening with your doctor. This might involve low-dose CT scans.

Environmental Precautions

- **Reduce Exposure to Carcinogens:**
- **Limit exposure to substances like asbestos, radon, and other harmful chemicals, especially in occupational settings.**
- **Ensure proper ventilation in homes and workplaces.**
- **Test your home for radon and take steps to reduce exposure if levels are high.**

Healthy Lifestyle Choices

- **Maintain a Healthy Diet:** A diet rich in fruits, vegetables, and whole grains can help boost your immune system.
- **Regular Exercise:** Physical activity can help reduce the risk of various cancers, including lung cancer.
- **Manage Stress:** Stress management techniques like meditation, yoga, or deep breathing can help reduce stress and improve overall health.

By adopting these preventive measures, you can significantly reduce your risk of developing lung cancer and improve your overall health.

patient's overall health, and the specific type of lung cancer.

To reduce the risk of lung cancer, it's essential to avoid smoking, limit exposure to secondhand smoke, and adopt a healthy lifestyle. Regular check-ups and early detection screening can also play a vital role in improving outcomes.

As research continues to advance, new and more effective treatments are being developed, offering hope for improved survival rates and quality of life for lung cancer patients.

REFERENCES

1. Hanahan D. Hallmarks of cancer: new dimensions. *Cancer Discov.* 2022;12(1):31–46. Doi:10.1158/2159-8290.CD-21-1059.
2. Kumar RMH. Childhood-Oncology Intelligence for Predicting Cancer Emergence, Optimizing Precision Therapies, and Simulating Lifelong Outcomes in Pediatric Malignancies Using Autonomous Foundation Models. *Int J Drug Deliv Technol.* 2026;16(65s):162-173. DOI:10.25258/ijddt.16.65s.19
3. Moor M, Banerjee O, Abad ZSH, et al. Foundation models for generalist medical artificial intelligence. *Nature.* 2023;616(7956):259–265. Doi:10.1038/s41586-023-05881-4.
4. Rajendran LKK. Hematological Malignancy Identification via K-means based ROI Extraction. *International Journal of Clinical Research in Medical Sciences.* 2026;1(2):1-10. Doi:10.67231/kt1w3e73.
5. Kumar RMH. Pan-System Cancer Intelligence: Integrating Blood, Immune, Microbiome, and Tumor Microenvironment Data Using Foundation Models. *Power System Protection and Control.* 2023;51(4):92-100. Doi:10.46121/pspc.51.4.8.
6. Rajendran LKK. Identifying Determinants of Outcome in Post-Radiotherapy Cervical Carcinoma Requiring Adjuvant Surgery. *International Journal of Clinical Research in Medical Sciences.* 2026;1(2):1-10. Doi:10.67231/3acej759.
7. Maradi Hemanth Kumar R. AI-Driven Liquid Biopsy Systems for Early Cancer Detection and Personalized Oncology. *Power System Protection and Control.* 2023;51(4):66-83. Doi:10.46121/pspc.51.4.7.
8. Rajendran LKK. Machine Learning-Driven Symptom-Based Cancer Risk Stratification: A Systematic Review of Clinical Prediction Models

- and Methodological Rigor. *Int J Drug Deliv Technol.* 2026;16(40s):242-253. Doi:10.25258/ijddt.16.40s.26.
9. Kumar RMH. Maternal–Fetal Oncology Intelligence: Self-Evolving Foundation Models and Digital Twin Ecosystems for Precision Cancer Prediction, Treatment Optimization, and Maternal–Fetal Outcome Forecasting. *Int J Drug Deliv Technol.* 2026;16(65s):174-185. DOI: 10.25258/ijddt.16.65s.20
 10. Rajendran OK. Bias, Fairness, and Ethical Challenges in Artificial Intelligence: A Comprehensive Review of Causes, Impacts, and Mitigation Strategies. *Scientific Culture.* 2026;12(2.1):13001-13010. Doi:10.5281/zenodo.20374091.
 11. Topol EJ. High-performance medicine: the convergence of human and artificial intelligence. *Nat Med.* 2019;25(1):44–56. Doi:10.1038/s41591-018-0300-7.
 12. Kumar RMH. Precision Oncofertility: Integrating Genomics, Reproductive Biomarkers, Treatment Toxicity Profiles, and Foundation Models for Fertility Preservation in Men and Women with Cancer. *Int J Drug Deliv Technol.* 2026;16(65s):186-200. DOI: 10.25258/ijddt.16.65s.21
 13. Rajendran OK. Clinical Translation of Artificial Intelligence in Oncology: Real-World Validation, Workflow Integration, and Precision Medicine Applications. *Int J Drug Deliv Technol.* 2026;16(49s):956-964. Doi:10.25258/ijddt.16.49s.110.
 14. Rajendran LKK. Interpretable Machine Learning for Early Mortality Prediction in Acute Myeloid Leukemia: A Decision Tree–Based Retrospective Cohort Study. *Int J Drug Deliv Technol.* 2026;16(40s):231-241. Doi:10.25258/ijddt.16.40s.25.
 15. Kumar RMH. Self-Evolving Digital Twin Ecosystems for Early Detection and Precision Management of Breast, Lung, Colorectal, and Ovarian Cancers. *Int J Drug Deliv Technol.* 2026;16(65s):201-212. DOI: 10.25258/ijddt.16.65s.22
 16. Esteva A, Robicquet A, Ramsundar B, et al. A guide to deep learning in healthcare. *Nat Med.* 2019;25(1):24–29. Doi:10.1038/s41591-018-0316-z.
 17. Rajendran OK. Generative AI for Synthetic Medical Image Generation in Oncology: Addressing Data Scarcity in AI-Driven Cancer Diagnosis. *Int J Drug Deliv Technol.* 2026;16(49s):1010-1016. Doi:10.25258/ijddt.16.49s.117.
 18. Rajendran LKK. Integrated Prognostic Modeling of Tumor Stage, Multimodal Therapy, and Functional Status in Lung Cancer Survival: A Real-World Cohort Study. *Scientific Culture.* 2026;12(5):567-576. Doi: 10.5281/zenodo.20738481.
 19. Bommasani R, Hudson DA, Adeli E, et al. On the opportunities and risks of foundation models. *arXiv.* 2021. Doi:10.48550/arXiv.2108.07258.
 20. Rajendran LKK. Integrative Pharmacogenomic Analysis of Drug Response Heterogeneity Across Cancer Cell Lines: Insights From Large-Scale GDSC Data. *Scientific Culture.* 2026;12(4):7537-7546. Doi:10.5281/zenodo.20767386.
 21. Acs B, Rantalainen M, Hartman J. Artificial intelligence as the next step towards precision pathology. *J Intern Med.* 2020;288(1):62–81. Doi:10.1111/joim.13030.
 22. Rajendran OK. Tumor Microenvironment Interaction-Guided Graph Neural Networks for Survival Prediction from Whole-Slide Pathology Images. *Int J Drug Deliv Technol.* 2026;16(49s):481-488. Doi:10.25258/ijddt.16.49s.50.
 23. Rajendran LKK. Evaluating the Association of Cancer-Related Risk Factors With Multisystem Health: Insights Into Fertility, Cardiovascular, and Renal Indicators. *Scientific Culture.* 2026;12(4):7520-7527. Doi:10.5281/zenodo.20767374.
 24. Rajendran LKK. From Prediction to Precision: An Externally Validated Deep Learning–Based Survival and Adjuvant Therapy Recommendation System for Resected Stage III Non–Small Cell Lung Cancer. *Int J Drug Deliv Technol.* 2026;16(30s):430-438. doi:10.25258/ijddt.16.30s.41.
 25. Kumar RMH. Multimodal foundation AI models in precision oncology: Integrating radiomics, pathomics, multi-omics, and clinical intelligence systems. *Power System Protection and Control.* 2024;52(4):189-204. doi:10.46121/pspc.52.4.16.
 26. Rajendran LKK. From Prediction to Practice: A Machine Learning–Based Clinical Decision Support Tool for Bevacizumab Risk Stratification in Oncology. *Int J Drug Deliv Technol.* 2026;16(30s):414-429. Doi:10.25258/ijddt.16.30s.40.
 27. Rajendran OK. Self-supervised multimodal Learning for early cancer detection across Imaging and genomics. *Power System Protection and Control.* 2024;52(4):167-178. Doi:10.46121/pspc.52.4.14.
 28. Rajendran OK. Explainable AI-Driven Clinical Decision Support Systems in Precision Oncology: Interpretable Models for Multimodal Cancer Care. *Scientific Culture.* 2026;12(2.1):12359-12369. Doi:10.5281/zenodo.20328194.
 29. Rajendran LKK. Impact of Treatment Modalities on Fertility, Sexual Function, and Psychological Outcomes in Testicular Cancer Survivors: A Comprehensive Review. *Int J Drug Deliv Technol.* 2026;16(30s):447-453. Doi:10.25258/ijddt.16.30s.43.
 30. Rajendran LKK. Intelligent Omics-Driven Patient Stratification for Cancer Therapeutic Re-profiling. *International Journal of Clinical Research in Medical Sciences.* 2026;1(1):1-11. Doi:10.67231/gv5hck05.
 31. Rajendran LKK. Cancer nanomedicine: utilizing the enhanced permeability and retention (EPR) effect to deliver high payloads of chemotherapeutic agents directly to tumor sites. *Power System Protection and Control.* 2024;52(2):123-129.

- Doi:10.46121/pspc.52.2.12.
32. Kather JN, Calderaro J. Development of AI in digital pathology. *Nat Rev Clin Oncol*. 2020;17(10):591–595. Doi:10.1038/s41571-020-00431-0.
 33. Rajendran OK. AI-based radiogenomic Models for predicting immunotherapy response In solid tumors. *Power System Protection and Control*. 2023;51(4):24-37. Doi:10.46121/pspc.51.4.4.
 34. Rajendran LKK. Enhanced Predictive Analytics for Early Malignancy Discovery in Routine Screening. *International Journal of Clinical Research in Medical Sciences*. 2026;1(1):1-10. Doi:10.67231/grams870.
 35. Rajendran OK. Machine Learning-Based Prediction of Chemotherapy Toxicity in Colorectal Cancer: A Personalized Risk Stratification Approach. *Scientific Culture*. 2026;12(5.1):942-952. Doi:10.5281/zenodo.20767359.
 36. Rajendran OK. Federated radiology AI Models for multi-institutional cancer diagnosis Without data sharing. *Power System Protection And Control*. 2023;51(4):38-54. Doi:10.46121/pspc.51.4.5.
 37. Kumar RMH. AI-augmented immuno-oncology: Foundation models for predicting immune response, resistance, and precision immunotherapy. *Power System Protection and Control*. 2024;52(2):193-208. doi:10.46121/pspc.52.2.18.
 38. Rajendran OK. Deep Reinforcement Learning in Oncology: Advances in Cancer Imaging, Radiotherapy, and Personalized Treatment. *Scientific Culture*. 2026;12(5):597-606. Doi:10.5281/zenodo.20767337.
 39. Rajendran OK. DEEP LEARNING FOR CROSS-MODALITY MAPPING BETWEEN HISTOPATHOLOGY AND RADIOLOGICAL IMAGING. *Power System Protection and Control*. 2025;53(3):313-328. Doi:10.46121/pspc.53.3.21.
 40. Lu MY, Chen TY, Williamson DFK, et al. AI-based pathology predicts origins for cancers of unknown primary. *Nature*. 2021;594(7861):106–110. Doi:10.1038/s41586-021-03512-4.
 41. Rajendran OK. Artificial Intelligence in Oncologic Imaging: Deep Learning, Radiomics, and Clinical Integration for Precision Cancer Diagnosis. *Int J Drug Deliv Technol*. 2026;16(50s):871-880. Doi:10.25258/ijddt.16.50s.92.
 42. Bilal M, Raza SEA, Azam A, et al. Development and validation of a weakly supervised deep learning framework to predict the risk of colorectal cancer recurrence from histology images. *Lancet Oncol*. 2021;22(11):153–163. Doi:10.1016/S1470-2045(21)00430-5.
 43. Rajendran OK. DIGITAL TWIN FRAMEWORKS FOR PERSONALIZED CANCER PROGRESSION MODELING USING LONGITUDINAL DATA. *Power System Protection and Control*. 2025;53(4):486-501. Doi:10.46121/pspc.53.4.33.
 44. Rajendran LKK. Genomic profiling: utilizing Multi-omics data to identify potential Therapeutic targets and resistance markers. *Power System Protection and Control*. 2024;52(4):159-166. Doi:10.46121/pspc.52.4.13.
 45. Rajendran OK. Artificial Intelligence–Driven Multimodal Imaging for Cancer During Pregnancy: Advances in Maternal–Fetal Diagnostics and Precision Oncology. *Int J Drug Deliv Technol*. 2026;16(50s):862-870. Doi:10.25258/ijddt.16.50s.91.
 46. Rajendran LKK. Immunotherapy and cell Therapy: developing CAR-T cell therapies and Other immune-based treatments for cancer and Autoimmune diseases. *Power System Protection and Control*. 2023;51(2):64-77. Doi:10.46121/pspc.51.2.7.
 47. Rajendran OK. FOUNDATION MODEL–DRIVEN PRECISION ONCOLOGY: INTEGRATING MULTI-OMICS, RADIOLOGY, AND CLINICAL DATA FOR PREDICTIVE CANCER CARE. *Power System Protection and Control*. 2024;52(2):154-163. Doi:10.46121/pspc.52.2.14.
 48. Rajendran LKK. Theranostics: integrating Diagnostic imaging agents and therapeutic Drugs into a single multifunctional nano-Platform for real-time monitoring of treatment. *Power System Protection and Control*. 2025;53(2):376-386. Doi:10.46121/pspc.53.2.31.
 49. Rajendran LKK. Mechanisms driving Immunotherapy resistance in colorectal cancer Liver metastases. *Power System Protection and Control*. 2024;52(1):29-37. Doi:10.46121/pspc.52.1.5.
 50. Hemanth Kumar RM. Integrated Transcriptomic and 3 Learning Framework Identifies a Blood-Based Biomarker Signature for Anthracycline-Induced Cardiotoxicity in Juvenile Cancer Survivors. *Int J Drug Deliv Technol*. 2026;16(40s):219-230. Doi:10.25258/ijddt.16.40s.24.
 51. Rajendran OK. DeepDRA: A Deep Learning Framework for Drug Repurposing and Cancer Drug Response Prediction Using Multi-Omics Data. *Scientific Culture*. 2026;12(3):68-77. Doi:10.5281/zenodo.12326001.